Quitting Time? The Role Failure Plays in Pharmaceutical InnovationsAllbiopro2018-11-07T08:46:06+09:0011월 7th, 2018|
Eli Lilly Pushes Full Steam Ahead on Immuno-Oncology With NextCure PactAllbiopro2018-11-07T08:45:39+09:0011월 7th, 2018|
In Busy Year in Oncology, Pfizer Partners With Nektar to Develop Three Combination DrugsAllbiopro2018-11-07T08:45:12+09:0011월 7th, 2018|
AstraZeneca Unloads Three Asthma and Rhinitis Drugs to Covis Pharma for $350 MillionAllbiopro2018-11-07T08:44:45+09:0011월 7th, 2018|
Comparing This Year’s Big Biotech IPOs to Previous YearsAllbiopro2018-11-07T08:44:17+09:0011월 7th, 2018|
J&J’s Janssen Inks Deal With Korea’s Yuhan for NSCLC Drug Valued at up to $1.25 BillionAllbiopro2018-11-07T08:43:51+09:0011월 7th, 2018|
Allergan Backs off From $200 Million Plant Expansion in Waco, TexasAllbiopro2018-11-07T08:43:24+09:0011월 7th, 2018|
ProBioGen Announces Successful Bispecific GlymaxX® Development Project for ZymeworksAllbiopro2018-11-07T08:42:57+09:0011월 7th, 2018|
FDA cited Akorn’s New Jersey plant even as drugmaker fought Fresenius in court over abandoned buyout Allbiopro2018-11-07T08:42:29+09:0011월 7th, 2018|
AstraZeneca’s rummage sale continues with $350M deal, its second in a weekAllbiopro2018-11-07T08:42:02+09:0011월 7th, 2018|
That generic Advair you’ve been expecting for months? It’ll come, but let’s talk other products, Mylan saysAllbiopro2018-11-07T08:41:35+09:0011월 7th, 2018|
Eylea crosses quarterly U.S. blockbuster line for Regeneron as Dupixent nears new FDA expansionAllbiopro2018-11-07T08:41:05+09:0011월 7th, 2018|
Eli Lilly’s new launches step up in time to fill the growing Cialis gapAllbiopro2018-11-07T08:40:36+09:0011월 7th, 2018|
Amgen taps Provention Bio to develop celiac disease drugAllbiopro2018-11-07T08:40:07+09:0011월 7th, 2018|
Achaogen cuts costs again and puts up ‘for sale’ signAllbiopro2018-11-07T08:39:39+09:0011월 7th, 2018|
Singapore swing: Lonza transfers Tracon Ab to single-use plantAllbiopro2018-11-07T08:38:44+09:0011월 7th, 2018|
